FY’20 results are slightly ahead of our expectations, and cap an excellent period with strong news flow. KidneyIntelX has now launched at Mount Sinai and is cleared to report results in all 50 US states. We continue to believe KidneyIntelX could represent the future standard-ofcare for early detection of chronic kidney disease progression and kidney failure in patients with Type II Diabetes, affecting an estimated 11m. Focus is now on building out the platform with expanded indicated uses, win n ....
27 Oct 2020
FY'20 results inline; updated forecasts post IPO
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
FY'20 results inline; updated forecasts post IPO
Renalytix Plc (RENX:LON) | 30.0 0 0.0% | Mkt Cap: 37.9m
- Published:
27 Oct 2020 -
Author:
Edward Thomason -
Pages:
3
FY’20 results are slightly ahead of our expectations, and cap an excellent period with strong news flow. KidneyIntelX has now launched at Mount Sinai and is cleared to report results in all 50 US states. We continue to believe KidneyIntelX could represent the future standard-ofcare for early detection of chronic kidney disease progression and kidney failure in patients with Type II Diabetes, affecting an estimated 11m. Focus is now on building out the platform with expanded indicated uses, win n ....